Tag Archives: Thing.’

They Thought Hemophilia Was a ‘Lifelong Thing.’ They May Be Wrong.

Now, though, researchers see the start of a new era. “It’s a really optimistic time,” said Dr. Lindsey A. George, a hematologist at the Children’s Hospital of Philadelphia and a principal investigator for Spark Therapeutics, one of several companies developing gene therapies for hemophilia. Imperfect successes The goal of gene therapy is to reduce or… Read More »